Patent Application
20150283180
Transplants of organs provide an important therapy for a variety of devastating diseases. However, the therapies are limited by rejection of the transplants by the immune system. Moreover, prolonged administration of immunosuppressive agents to prevent rejection can produce renal or hepatic toxicity and increase the susceptibility to malignancies or infections. One recent strategy for improving transplants of cells and organs is the administration of mesenchymal stem/progenitor cells (MSCs). Systemic infusion of MSCs was reported to decrease the graft rejection in animal models, and the results have prompted a number of clinical trials in patients.1-4 Previous studies largely attributed the improved survival of transplants to the immunomodulatory effects of MSCs.3-6 Most of the data, however, were based on the in vitro experiments that may or may not reflect actions of the MSCs in vivo.
In order to define how MSCs might improve the engraftment of organ transplants, we here adopted a mouse model of allogeneic corneal transplantation, a model in which the temporal sequence of events from the introduction of the alloantigen to immune rejection is distinct and well-established.7-9 We demonstrated that intravenous (IV) administration of human MSCs (hMSCs) at the time of gaffing decreased the immune rejection and prolonged the survival of corneal allograft primarily by suppressing the surgery-induced inflammation in the early postoperative period. Suppression of inflammation subsequently inhibited the afferent loop of the alloimmune response. Of special interest was that the beneticial effects of the MSCs were observed without the cells being engrafted in the cornea, but they were dependent on MSCs trapped in the lungs after IV infusion being activated to express the gene for the anti-inflammatory protein TSG-6.
In accordance with an aspect of the present invention, there is provided a method of preventing or treating rejection of a corneal transplant in an animal. The method comprises administering to an animal a composition comprising mesenchymal stem cells, or MSCs. The mesenchymal stem cells are present in the composition in an amount effective to prevent or treat rejection of a comeal transplant in an animal.
In a non-limiting embodiment, the mesenchymal stem cells are administered to the animal prior to the corneal transplant. In another non-limiting embodiment, the mesenchymal stem cells are administered to the animal concurrently with the corneal transplant. In yet another non-limiting embodiment, the mesenchymal stem cells are administered to the animal subsequent to the corneal transplant.
In a further non-limiting embodiment, the mesenchymal stem cells are administered to the animal prior to and concurrently with the corneal transplant. In another non-limiting embodiment, the mesenchymal stem cells are administered to the animal prior to and subsequent to the corneal transplant. In another non-limiting embodiment, the mesenchymal stem cells are administered to the animal concurrently with and subsequent to the corneal transplant. In yet another non-limiting embodiment, the mesenchymal stem cells are administered to the animal prior to, concurrently with, and subsequent to the corneal transplant.
In another non-limiting embodiment, the mesenchymal stem cells are administered to the animal one day before and immediately after the corneal transplant.
The mesenchymal stem cells may be administered to any animal having an eye with a cornea. Such animals include mammals, including human and non-human primates, birds, reptiles, amphibians and fish.
The MSCs can be obtained from any source. The MSCs may be autologous with respect to the recipient (obtained from the same host) or allogeneic with respect to the recipient. In addition, the MSCs may be xenogeneic to the recipient (obtained from an animal of a different species), for example rat MSCs may be used to treat or prevent transplant rejection, including corneal transplant rejection, in a human.
In a further non-limiting embodiment, MSCs used in the present invention can be isolated, from the bone marrow of any species of mammal, including but not limited to, human, mouse, rat, ape, gibbon, bovine. In a non-limiting embodiment, the MSCs are isolated from a human, a mouse, or a rat. In another non-limiting embodiment, the MSCs are isolated from a human.
Any medium capable of supporting MSCs in vitro may be used to culture the MSCs. Media formulations that can support the growth of MSCs include, but are not limited to, Dulbecco's Modified Eagle's Medium (DMEM), alpha modified Minimal Essential Medium (αMEM), and Roswell Park Memorial Institute Media 1640 (RPMI Media 1640) and the like. Typically, 0 to 20% fetal bovine serum (FBS) or 1-20% horse serum is added to the above medium in order to support the growth of MSCs. A defined medium, however, also can be used if the growth factors, cytokines, and hormones necessary for culturing MSCs are provided at appropriate concentrations in the medium. Media useful in the methods of the invention may contain one or more compounds of interest, including but not limited to antibiotics, mitogenic or differentiation compounds useful for the culturing of MSCs. The cells may be gown in one non-limiting embodiment, at temperatures between 27° C. to 40° C., in another non-limiting embodiment at 31° C. to 37° C., and in another non-limiting embodiment in a humidified incubator. The carbon dioxide content may be maintained between 2% to 10% and the oxygen content may be maintained between 1% and 22%; however, the invention should in no way be construed to be limited to any one method of isolating and culturing MSCs. Rather, any method of isolating and culturing MSCs should be construed to be included in the present invention.
Antibiotics which can be added into the medium include, but are not limited to, penicillin and streptomycin. The concentration of penicillin in the culture medium is about 10 to about 200 units per ml. The concentration of streptomycin in the culture medium is about 10 to about 200 μg/ml.
Once the mesenchymal stem cells are obtained from a source as hereinabove described, and are cultured to provide a sufficient number of mesenchymal stem cells, the mesenchymal stem cells are administered to the animal to treat rejection of the corneal transplant.
The mesenchymal stem cells are administered by any of a variety of acceptable means of administration known to those of ordinary skill in the art. Such methods include, but are not limited to, intravenous, intraperitoneal, intramuscular, intradermal, subcutaneous or topical administration.
Although the scope of the present invention is not intended to be limited to any theoretical reasoning, Applicants have discovered that, when mesenchymal stem cells are administered to an animal to prevent or treat rejection of a corneal transplant, the mesenchymal stem cells are activated in vivo to increase significantly expression of the anti-inflammatory protein known as tumor necrosis factor stimulated gene 6 protein, or TSG-6 protein, which reduces inflammation induced as a result of the corneal transplant. It is believed further that, by reducing inflammation induced as a result of the corneal transplant, the engraftment of the transplanted cornea is facilitated and improved. Thus, in another non-limiting embodiment, the mesenchymal stem cells are administered in combination with at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof. In another non-limiting embodiment, the at least one anti-inflammatory protein is TSG-6 protein or a biologically active fragment, derivative, or analogue thereof.
As noted hereinabove, it is believed that TSG-6 protein reduces inflammation induced by a corneal transplant, thereby improving the engraftment of the transplanted cornea. It is believed further that anti-inflammatory proteins, such as TSG-6, may improve the engraftment of and/or treat or prevent the rejection of other cells, tissues, or organs, as well as aid in the survival of implants of prostheses or alleviate inflammation induced by surgery.
Thus, in accordance with another aspect of the present invention, there is provided a method of preventing and/or treating rejection of a transplanted cell, tissue, or organ in an animal. The method comprises administering to the animal at least one anti-inflammatory protein or a biologically active fragment, derivative, or analogue thereof. The at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof is administered in an amount effective to prevent and/or treat rejection of the transplanted cell, tissue, or organ in the animal.
In a non-limiting embodiment, the at least one anti-inflammatory protein is TSG-6 protein or a biologically active fragment, derivative, or analogue thereof. Such biologically active fragments, derivatives, and analogues of TSG-6 protein include, but are not limited to, the TSG-6 link module (i.e., amino acid residues 1 through 133 of the “native” human TSG-6 protein), and TSG-6 protein or biologically active fragments, derivatives, or analogues thereof having at least one histidine residue at the C-terminal thereof. In a non-limiting embodiment, the TSG-6 protein or fragment, derivative, or analogue thereof has a “His-tag” of six histidine residues at the C-terminal thereof.
Native human TSG-6 protein has the following amino acid sequence:
The TSG-6 link module consists of amino acid residues 1 through 133 of the above sequence.
In a non-limiting embodiment, the at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof, is administered prior to the transplant of the cell, tissue, or organ. In another non-limiting embodiment, the anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof is administered concurrently with the transplanted cell, tissue, or organ. In yet another non-limiting embodiment, the at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof is administered subsequent to the transplant of the cell, tissue, or organ.
In another non-limiting embodiment, the at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof is administered prior to and concurrently with the transplant of the cell, tissue, or organ. In another non-limiting embodiment, the at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof is administered prior to and subsequent to the transplant of the cell, tissue, or organ. In yet another non-limiting embodiment, the at least one anti-inflammatory protein or fragment, derivative, or analogue thereof is administered prior to, concurrently with, and subsequent to the transplant of the cell, tissue, or organ.
The at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof may be administered to any animal that is a recipient of a transplant of a cell, tissue, or organ. Such animals include those hereinabove described, including mammals, and including human and non-human primates.
The at least one anti-inflammatory protein, or biologically active fragment, derivative, or analogue thereof is administered to prevent and/or treat rejection of any cell, tissue, or organ. Such cells, tissues, or organs include, but are not limited to, bone marrow cells, islet cells, including Langerhans cells, pancreatic Beta cells, cornea, skin, heart, lung, liver, kidney, and pancreas.
In another non-limiting embodiment, the at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof is administered in combination with mesenchymal stem cells in order to prevent and/or treat rejection of a transplanted cell, tissue, or organ.
The at least one anti-inflammatory protein, or biologically active fragment, derivative, or analogue thereof is administered by any acceptable means known to those skilled in the art, such as intravenous, peritoneal, intramuscular, intradermal, subcutaneous, or topical administration.
The mesenchymal stem cells and/or the at least one anti-inflammatory protein, such as TSG-6 protein or a biologically active fragment, derivative, or analogue thereof, may be administered to the animal in combination with various anti-infective agents, such as anti-bacterial, anti-viral, or anti-fungal agents in order to treat and/or prevent infections that may occur as a result of the transplant of the cell, tissue, or organ.
In general, the at least one anti-infective agent which is administered in combination with the at least one anti-inflammatory protein or mesenchymal stem cells of the present invention depends upon the type of infection, e.g., bacterial, viral, or fungal, the type or species of bacterium, virus, or fungus associated with the infection, and the extent and severity of the infection, and the age, weight, and sex of the patient.
In a non-limiting embodiment, when the infection is associated with one or more bacteria, at least one anti-infective agent which is administered in combination with the at least one anti-inflammatory protein or mesenchymal stem cells of the present invention is at least one anti-bacterial agent. Anti-bacterial agents which may be administered include, but are not limited to, quinolone antibiotics, such as, for example, ciprofloxacin, levotloxacin (Cravit), moxifloxacin (Vigamox), gatifloxacin (Zy-mar), cephalosporin, aminoglycoside antibiotics (e.g., gentamycin), and combinations thereof.
In another non-limiting embodiment, when the infection is associated with one or more viruses, the anti-infective agent which is administered in combination with the at least one anti-inflammatory protein or mesenchymal stem cells of the present invention is at least one anti-viral agent. Anti-viral agents which may be employed include those which are known to those skilled in the art.
In another non-limiting embodiment, when the infection is associated with one or more fungi, the anti-infective agent which is administered in combination with the at least one anti-inflammatory protein or mesenchymal stem cells of the present invention is at least one anti-fungal agent. Anti-fungal agents which may be employed include, but are not limited to, natamycin, amphotericin B, and azoles, including fluconazole and itraconzole.
In yet another non-limiting embodiment, when the infection is associated with more than one of bacteria, viruses, and fungi, more than one of anti-bacterial, anti-viral, and anti-fungal agents are administered in combination with the at least one anti-inflammatory protein or mesenchymal stem cells of the present invention.
In another non-limiting embodiment, the at least one anti-inflammatory protein, or biologically active fragment, derivative, or analogue thereof, such as TSG-6 protein or a biologically active fragment, derivative, or analogue thereof and/or mesenchymal stem cells may be administered in combination with one or more known pharmaceutically active agents used to treat and/or prevent transplant rejection. Such agents include, but are not limited to, anti-inflammatory agents, including non-steroidal anti-inflammatory drugs (NSAIDs), steroids, unoregulators, and immunosuppressive agents, such as, for example, cyclosporin, and anti-T-cell antibodies, and small interfering RNAs (siRNAs) that interfere with the expression of agents that exacerbate the effects of transplant rejection.
The mesenchymal stem cells and/or the at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof, such as TSG-6 protein or a biologically active fragment, derivative, or analogue thereof, is administered in conjunction with an acceptable pharmaceutical carrier.
Suitable excipients for injection solutions are those that are biologically and physiologically compatible with the MSCs and/or anti-inflammatory protein and with the recipient, such as buffered saline solution or other suitable excipients. The composition for administration can be formulated, produced and stored according to standard methods complying with proper sterility and stability.
The dosage of the MSCs and/or anti-inflammatory protein varies within wide limits and may be adjusted to the individual requirements in each particular case. The number of cells and/or amount of anti-inflammatory protein used depends on the weight and condition of the recipient, the number and/or frequency of administrations, and other variables known to those of skill in the art, including, but not limited to, the age and sex of the patient, the type of transplant rejection being prevented or treated, and the extent and severity thereof.
In one non-limiting embodiment, the invention provides a method for treating and/or preventing rejection of a transplant of a cell, tissue, or organ comprising providing a composition comprising purified tumor necrosis factor-alpha stimulated gene 6 (TSG-6) protein or a biologically active fragment or derivative or analogue thereof, to an animal, thereby preventing or reducing one or more symptoms of inflammation associated with rejection of the transplanted cell, tissue, or organ.
The at least one anti-inflammatory protein can be obtained by any method. For example, in a non-limiting embodiment, the protein can be purified from a transgenic cell that (a) comprises a heterologous nucleotide sequence encoding the protein, and (b) expresses the protein.
Any cell that may be transformed to express a heterologous nucleotide sequence may be used to express, for example, TSG-6 protein, or a biologically active fragment derivative or analogue thereof. Such cells include human and non-human eukaryotic animal cells. In another embodiment, the cell is a non-human eukaryotic animal cell.
In another non-limiting embodiment, the at least one anti-inflammatory protein may be synthesized by an automatic protein or peptide synthesizer by means known to those skilled in the art.
It will also be appreciated that fragments or variants or analogues of the above-mentioned proteins differing in sequence from their naturally occurring counterparts but retaining their biological activity can also be used.
In certain non-limiting embodiments of the invention, a fragment or variant or analogue of a naturally occurring anti-inflammatory protein is at least 70% identical, at least 80% identical, at least 90% identical, at least 95% identical, over an amino acid portion that constitutes at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, or 100% of the length of the naturally occurring counterpart. For example, variant that exhibits at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or greater sequence identity, over the relevant portion of the sequence could be used, wherein % identity is determined as described above. The amino acid portion, in a non-limiting embodiment, is at least 20 amino acids in length, and in another non-limiting embodiment, at least 50 amino acids in length. Alternately, a fragment or variant can display significant or, preferably, substantial homology to a naturally occurring counterpart. Generally a ent or variant of a naturally occurring anti-inflammatory protein possesses sufficient structural similarity to its naturally occurring counterpart that it is recognized by an antibody (e.g., a polyclonal or monoclonal antibody) that recognizes the naturally occurring counterpart.
In a non-limiting embodiment, the at least one anti-inflammatory protein, such as TSG-6 protein or a biologically active fragment, derivative, or analogue thereof, may be administered to the eye topically, such as, for example, in the form of eye drops, in order to treat or prevent rejection of a corneal transplant.
Various modifications or derivatives of the at least one anti-inflammatory protein, such as addition of polyethylene glycol chains (PEGylation), may be made to influence their pharmacokinetic and/or pharmacodynamic properties.
To administer the at least one anti-inflammatory protein by other than parenteral administration, the protein may be coated or co-administered with a material to prevent its inactivation. For example, the protein may be administered in an incomplete adjuvant, co-administered with enzyme inhibitors or administered in liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, disopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water, CGF emulsions, as well as conventional liposomes (Strejan, et al. (1984) J. Neuroimmunol. 7:27).
Although the compositions of this invention can be administered in simple solution, they are more typically used in combination with other materials such as carriers, preferably pharmaceutical carriers. Useful pharmaceutical carriers can be any compatible, non-toxic substance suitable for delivering the compositions of the invention to a patient. Sterile water, alcohol, fats, waxes, and inert solids may be included in a carrier. Pharmaceutically acceptable adjuvants (buffering agents, dispersing agents) may also be incorporated into the pharmaceutical composition. Generally, compositions useful for parenteral administration of such drugs are well known; e.g., Remington's Pharmaceutical Science, 17th Ed. (Mack Publishing Company, Easton, Pa., 1990). Alternatively, compositions of the invention may be introduced into a patient's body by implantable drug delivery systems [Urquhart et al., Ann. Rev. Pharmacol. Toxicol. 24:199 (1984).
Therapeutic formulations may be administered in many conventional dosage formulations. Formulations typically comprise at least one active ingredient, together with one or more pharmaceutically acceptable carriers.
The formulations conveniently may be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman et al. (eds.) (1990), The Pharmacological Bases of Therapeutics, 8th Ed Pergamon Press; and Remington's Pharmaceutical Sciences, supra, Easton, Pa.; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications Dekker, N.Y.; Lieberman et al. (eds.) (1990), Pharmaceutical Dosage Forms: Tablets, Dekker, N.Y.; and Liebeinian et al. (eds.) (1990), Pharmaceutical Dosage Forms: Disperse Systems, Dekker, N.Y.
In another non-limiting embodiment, the mesenchymal stem cells or therapeutic proteins employed for treating or preventing rejection of a transplanted cell, tissue, or organ may be contained in a nanoparticle. Such nanoparticles may be formed by methods known to those skilled in the art, and administered by methods such as those hereinabove described.
The invention now will be described with respect to the drawings. It is to be understood, however, that the scope of the present invention is not intended to be limited thereby.
A standard curve of the expression levels of human-specific GAPDH (hGAPDH) in the mouse cornea was constructed by adding known numbers of hMSCs to the lung from a single mouse. The expression of hGAPDH was evaluated by real-time RT-PCR to establish a standard curve. The level of hGAPDH was assayed in the lungs at 10 hours after 1×106 hMSCs were injected IV twice into mice one day before and immediately after corneal allotransplantation surgery. The asterick indicated the mean level of hGAPDH detected in the lungs from mice treated with hMSCs, demonstrating that about 100,000 human cells (10% of injected cells) were present.
The invention now will be described with respect to the following examples; however, the scope of the present invention is not intended to be limited thereby.
Vials of frozen passage one hMSCs were obtained from the Center for the Preparation and Distribution of Adult Stem Cells (http://medicine.tamhsc.edu/irm/msc-distribution.html) that supplies standardized preparations of MSCs enriched for early progenitor cells to over 300 laboratories under the auspices of an NIH/NCRR grant (P40 RR 17447-06). All of the experiments were performed with hMSCs from one donor. The cells differentiated consistently into three lineages in culture, were negative for hematopoietic markers (CD34, CD36, CD117 and CD45), and were positive for mesenchymal markers CD29 (95%), CD44 (>93%), CD49c (99%), CD49f (>70%), CD59 (>99%), CD90 (>99%), CD105 (>99%) and CD166 (>99%). Following culture at high density for 24 hours to recover viable cells, hMSCs were plated at low density (100 cells/cm2), incubated in complete culture medium (CCM) with 16% FBS for 8 days until approximately 70% confluence was reached, and harvested with 0.25% trypsin/1 mM EDTA at 37° C. for 2 min. The trypsin thereafter was inactivated by adding the CCM to the cells, and the cells were washed with PBS by centrifugation at 1,200 rpm for 5 min. The cells were frozen in α-MEM with 30% FBS and 5% DMSO at a concentration of 1×106 cells/mL. Passage two cells were used for all experiments. Following lifting the cells prior to injection, a final wash was performed using Hank's Balanced Salt Solution (HBSS; BioWhittaker, Walkersville, Md.). After washing by centrifugation, the cells were suspended in HBSS at a concentration of 10,000 cells/4 for injection.
For siRNA experiments, hMSCs were transfected with siRNA for TSG-6 (sc-39819; Santa Cruz Biotechnology, Santa Cruz, Calif.) or scrambled siRNA (Stealth™ RNAi Negative Control; Invitrogen, Carlsbad. Calif.) with a commercial kit (Lipofectamine RNAiMAX reagent; Invitrogen). To confirm successful knock-down of TSG-6 expression, RNA was extracted from aliquots of the cells (RNeasy Mini kit; Qiagen, Valencia, Calif.) and assayed for TSG-6 by real-time RT-PCR. The knockdown efficiency of TSG-6 in hMSCs was 82 to 85% from 10 to 24 hours after the start of transfection (
The experimental protocols were approved by the Institutional Animal Care and Use Committee of Texas A&M Health Science Center and Seoul National University Hospital Biomedical Research Institute. Eight-week-old female B6 mice (C57BL/6J, H-2b, Charles River Laboratories International, Inc. Wilmington, Mass.) were used as corneal donors and BALB/c mice (BALB/cAnNCrl, H-2d, Charles River Laboratories International, Inc.) served as comeal transplant recipients.
Central 2-mm diameter corneal grafts were excised from donor corneas of B6 mice using a 2.0 mm trephine (Katena Products, Inc., Denville, N.J.). The recipient corneal graft bed was prepared by removing a central 1.5-mm diameter button in recipient corneas of BALB/c host mice with a 1.5 mm trephine (Katena Products. Inc.). The prepared donor corneal grafts were placed in the recipient bed and secured with eight interrupted 11-0 nylon sutures. Syngeneic autografts (BALB/c-to-BALB/c) served as experimental controls and were performed in the same fashion. The lids were closed with an 8-0 nylon tarsorrhaphy which was maintained (except for clinical evaluation) until graft rejection developed. All galls were evaluated three times weekly for 6 weeks. Graft rejection was defined as a complete loss of graft transparency (i.e., the pupil margin and iris structure are not visible through the graft). Recipient mice received 1×106 hMSCs in 100 μL HBSS via tail vein either once (immediately after surgery) or twice (one day before surgery and immediately after surgery). HBSS was injected IV in the control group. For IV TSG-6 experiments, each mouse received 35 μg of recombinant human (rh)TSG-6 (R&D Systems, Minneapolis, Minn.) in 100 μL PBS or PBS 100 μL via tail vein
For tissue extraction, following sacrifice of the mice, the cornea was excised and fixed in 10% paraformaldehyde. The cornea was cut into 4 μm sections and stained with H&E or subjected to immunohistochemistry. The formalin-fixed corneal sections were deparaffinized with ethanol and antigen was retrieved using a steamer in epitope retrieval solution (IHC WORLD, Woodstock, Md.). Primary antibodies used were as follows: rabbit polyclonal antibody to CD3 (ab5690, Abcam, Cambridge, Mass.), rat monoclonal antibody to F4/80 (ab6640. Abcam), rabbit polyclonal antibody to iNOS (ab15323, Abcam), mouse monoclonal antibody to MRC (ab8918, Abcam), and mouse monoclonal antibody to MHC class II 1 Ad (ab64531, Abcam). A DAPI solution (VECTASHIELD Mounting Medium: Burlingame, Calif.) was used for counterstaining.
For RNA extraction, the cornea or lung was minced into small pieces, lysed in RNA isolation reagent (RNA Bee, Tel-Test Inc., Friendswood, Tex.), and homogenized using a motor-driven homogenizer. Total RNA was then extracted using RNeasy Mini kit (Qiagen) and used to synthesize double-stranded cDNA by reverse transcription (SuperScript III, Invitrogen). Real-time amplification was performed using TaqMan Universal PCR Master Mix (Applied Biosystems, Carlsbad, Calif.). An 18s rRNA probe (TaqMan Gene Expression Assays ID, Hs03003631_g1) was used for normalization of gene expression. For all the PCR probe sets, TaqMan Gene Expression Assay kits were purchased from Applied Biosystems. The assays were performed in triple technical replicates for each biological sample.
Real-Time RT-PCR Standard Curve for hGAPDH
A standard curve was generated by adding serial dilutions of hMSCs to mouse tissue as previously described. (Roddy, 2011; Lee, 2009). Briefly, 10-100,000 hMSCs were added to a mouse cornea. Following RNA extraction (RNeasy Mini kit; Qiagen), cDNA was generated by reverse transcription (SuperScript III; Invitrogen) using 1 μg total RNA. A human-specific GAPDH (hGAPDH) primer and probe set (TaqMan Gene Expression Assays ID, GAPDH HS99999905—05) was used. The values were normalized to total eukaryotic 18s rRNA. The standard curve was made based on hGAPDH expression from a known number of hMSCs added to one mouse cornea.
For protein extraction, the cornea was minced into small pieces and lysed in tissue extraction reagent (Invitrogen) containing protease inhibitor cocktail (Roche, Indianapolis, Ind.). The samples were sonicated on ice (Ultrasonic Processor, Cole Parmer Instruments, Vernon Hills Ill.). After centrifugation at 12,000 rpm at 4° C. for 20 min, the supernatant was collected and assayed by ELISA for IL-1β, IFN-γ, and IL-12p70 (Mouse Duoset kit; R&D Systems, Minneapolis, Minn.), CCR7 (USCN Life Science, Inc., Missouri City, Tex.), and MPO (HyCult biotech, Plymouth Meeting, Pa.).
DLNs were harvested from transplanted animals at days 7 and 28 after surgery. Each sample from an individual animal was prepared and anlayzed separately. No pooling of lymph node cells between animals was done. DLNs were placed and minced between the frosted ends of two glass slides in RPMI media containing 10% FBS and 1% penicillin-streptomycin. Cell suspensions were collected, and incubated for 30 min at 4° C. with fluorescein-conjugated anti-mouse antibodies. The primary antibodies used were as follows: I-Ad-PE, CD11b-FITC, CD11c-allophycocyanin, CD3-FITC, CD4-PE, and CD8-allophycocyanin (eBioscience, San Diego, Calif.). Three color phenotypic analyses were performed using a FACSCan to flow cytometer (BD BioSciences, Mountain View, Calif.). A total of 20,000 events from each sample were collected. The gate was set on either I-Ad+ or CD3 cell population, and further analysis of surface markers was done within this gate. Data were analyzed using Flowjo program (Tree Star, Inc., Ashland, Oreg.).
Survival analysis was performed using SPSS software (SPSS 12.0, Chicago, Ill.). The Kaplan-Meier method was used to evaluate the overall cumulative probability of graft survival, and the life-table method was used to estimate the median time to graft rejection. The raft survival between the groups was compared using the Breslow (Generalized Wilcoxon) test. Comparisons of parameters other than graft survival were made among the groups using one-way ANOVA using SPSS software. Differences were considered significant at p<0.05.
IV hMSCs Prolonged the Survival of Corneal Allografts
To determine whether IV hMSCs prolong the survival of corneal allografts, we performed orthotropic corneal allotransplantation using C57BL/6 mice (H-2b) as donors and BALB/c (H-2d) as recipients. Recipient mice received 1×106 hMSCs IV either once immediately after surgery (day 0) or twice at one day before surgery (day −1) and again immediately after surgery (day 0). Hank's Balanced Salt Solution (HBSS) was injected IV as a vehicle control. Syngeneic corneal autografts (BALB/c-to-BALB/c) were performed to serve as negative controls. For the follow-up period of 42 days. 7 of 12 B6 corneal grafts in BALB/c mice (allografts) were rejected within 28 days with a mean survival time of 21.3 days, while all of the BALB/c corneal gratis in BALB/c mice (auto afts, n=12) survived (
We performed histological studies on the grafts at day 28. In the rejected allografts of HBSS-injected animals, hematoxylin-eosin (H&E) staining of sections showed extensive infiltration of inflammatory cells (
Therefore, the data demonstrated that peri-transplant injection of IV hMSCs prolonged the survival of corneal allografts and prevented rejection. Two injections (day −1 and day 0) were more effective than a single injection (day 0).
IV hMSCs Suppressed Early Inflammation and Late Rejection of Corneal Allografts
In order to examine the effects of hMSCs, we analyzed corneal grafts for the time course of expression of inflammation- and immune-related molecules. Because the rejection of corneal allografts occurred by day 28 and the surviving grafts remained free of rejection after day 28 (
Therefore, the results indicated that hMSCs suppressed the surgery-induced inflammation in the early postoperative period and, apparently as a result, decreased the subsequent immune rejection of corneal allografts.
IV hMSCs Decreased Activation of Antigen Presenting Cells
Previous studies demonstrated that the principal antigen-presenting cells (APCs) of the cornea. Langerhans cells (LCs) reside in basal epithelium in the limbal area of the cornea. (Forrester, et al., Immunol. Rev Vol. 234, pgs. 282-304 (2010)). Also, CD11b CD11c+ cells having dendritic morphology are present in the anterior stroma, and a population of CD11b CD11c+ cells having macrophage morphology is present in the posterior stroma. (Hamrah, et al., J. Leukocyte Biol., Vol. 74, pgs. 172-178 (2003)). In response to inflammatory insults including transplantation surgery, APCs undergo maturation by overexpressing major histocompatibility complex (MHC) class H. (Dana, Invest. Ophthalmol. Vis. Sci., Vol. 45, pgs. 722-727 (2004); Dana, Trans. Am. Ophthalmol. Soc., Vol. 105, pgs. 330-343 (2007)). Activated APCs, most of which are of host origin, take up graft-derived antigens in the cornea and migrate to DLNs, where they present antigens to host T cells causing the T cell-mediated immune rejection. (Forrester. 2007: Kuffova, et al., J. Immunol., Vol. 180, pgs. 1353-1361 (2008)). Thus, we next examined whether the decrease in inflammation by IV hMSCs might lead to a reduction in the activation of APCs in the cornea and DLNs. First, we examined the whole-mounted epithelial sheets of the cornea for host-derived MHC class II (murine Iad) at one week after transplantation. We selected the one-week time-point, because it is the time at which allosensitization takes place and allorejection is not yet initiated. (Forrester, 2007). Therefore, it allowed us to examine the afferent sensitization arm of alloimmunity. Immunostaining showed that the number of MHC class II cells in the cornea was markedly lower in the allografts from mice treated with hMSCs, compared to the autografts or allografts without hMSCs (
IV Administered hMSCs Did not Engraft in the Corneal Allografts.
Previous reports showed that the vast majority of hMSCs infused IV in mice were trapped in lungs and disappeared with a half-life of about 24 hours without long-term engraftment into injured tissues such as the cornea or heart. (Roddy, et al Stem Cells, Vol. 29, pgs. 1572-1579 (2011); Lee, et al., Cell Stem Cell, Vol. 5, pgs. 54-63 (2009)). To determine whether hMSCs engrafted in the transplanted cornea after IV injection, we carried out quantitative RT-PCR assays for human-specific GAPDH in the corneas from mice that received two IV infusions of 1×106 hMSCs at day −1 and day 0 of corneal transplantation (
IV hMSCs Trapped in Lungs were Activated to Express the Anti-Inflammatory Gene/Protein TSG-6
Because the majority of IV hMSCs were trapped in lungs (Lee, 2009) and did not engraft in the cornea (
hMSCs with TSG-6 siRNA Knockdown Did not Either Reduce the Early Inflammation or Prolong Allograft Survival.
To explore the role of TSG-6 in preventing graft rejection, we knocked down the expression of TSG-6 in hMSCs by transient transfection with siRNA and injected the cells into mice with conical allografts at day −1 and day 0 of surgery. Three out of 6 allografts were rejected in mice that received a two-time injection of hMSCs with TSG-6 knockdown, whereas all (6/6) of the allografts remained free of rejection at 28 days in mice that received a two-time injection of hMSCs with scrambled siRNA control (p=0.047, Generalized Wilcoxon test) (
Next, we tested the hypothesis that systemically-administered rhTSG-6 could reproduce the effects of IV hMSCs by reducing the surgery-induced inflammation in corneal allografts. We administered 35 μg of rhTSG-6 in 100 μl PBS by tail vein injection immediately after corneal allotransplantation. The survival of corneal allografts was prolonged significantly in mice treated with rhTSG-6, compared to PBS-injected controls (the mean survival time: 25.6±1.5 days in the TSG-6 treated grafts and 18.6±3.1 days in the PBS-treated grafts; p=0.042; Generalized Wilcoxon test) (
As summarized in
Our data are consistent with the current paradigm that hMSCs can produce therapeutic benefits without engraftment into injured tissues and primarily by up-regulating the genes that modulate excessive inflammatory and immune reactions. (Prockop, et al., J. Cell. Mol. Med., Vol. 14, pgs. 2190-2199 (2010); Uccelli, et al., Curr. Opin. Immunol., Vol. 22, pgs. 768-774 (2010). In the present experiment, the multi-functional anti-inflammatory protein TSG-6 (Milner, et al., Biochem. Soc. Trans., Vol. 34, pgs. 446-450 (2006); Wisniewski, et al., Cytokine Growth Factor, Rev., Vol. 15, pgs. 129-146 (2004) accounted for beneficial effects of the hMSCs that were infused IV. Since pro-inflammatory cytokines, including IL-1, play a critical role in recruitment, activation, and migration of APCs such as LCs (Dana, 2004; Dana, 2007), suppression of inflammation early after grafting by hMSCs might contribute to a prolonged survival of corneal allografts through inhibition of the afferent loop of the immune response.
In addition to suppressing inflammation. MSCs also may have other effects on the immune system. A large number of in vitro and in vivo data demonstrate that MSCs can be immunosuppressive through their interaction with a broad range of immune cells (T and B cells, regulatory T cells, NK cells. DCs, macrophages, and neutrophils) and by secreting a number of molecules such as IDO, PGE2, nitric oxide. CCL2. TGF-β, TSG-6, IL-10, or HLA-G. 2010; Siegel, et al., Transplantation, Vol. 87, pgs. 545-549 (2009); Ren, et al., Cell Stem Cell, Vol. 2, pgs. 141-150 (2008): Rafei, et al., J. Immunol., Vol. 182, pgs. 5994-6002 (2009): Crop, et al., Transpl. Int., Vol. 22, pgs. 365-376 (2009)), This considerable diversity and discrepancy in experimental findings for the immune-modulatory mechanisms of MSCs probably reflects their remarkable ability to respond to the microenvironments of injured tissues. In the present experiment, we injected hMSCs IV one day prior to and at the time of transplantation. Although the cells rapidly disappeared from the system after injection (Lee. 2009), the MSCs decreased the early surgery-induced inflammation significantly by up-regulating the anti-inflammatory molecule TSG-6. Notably, in our present experimental setting, the expression of immunomodulatory and anti-inflammatory molecules that have been shown previously to the secreted by MSCs (COX2. NOS2. 100, CCL2, TGF-β, STC-1, and PTX3) was not up-regulated in hMSCs at the transcriptional level. We cannot rule out, however, the possibility that consistent expression of molecules other than TSG-6 at protein levels might contribute to the action of hMSCs observed in the current study. Similar results were obtained with IV recombinant TSG-6. Also, administration of hMSCs may have pre-conditioned the complex systems for inflammatory and immune responses so that the effects were apparent atter most of hMSCs no longer were detected.
One of the critical observations here was that the hMSCs were more effective if they were infused IV both the day before surgery and immediately after the surgery than if they were infused only immediately after the surgery. The result may reflect the fact that hMSCs do not express therapeutic proteins such as TSG-6 in culture unless activated by pro-inflammatory cytokines such as TNF-α or IFN-γ, and they are not activated to express TSG-6 until about 10 hours after they are trapped in the lungs following IV infusion. (Lee, 2009). Therefore, the preoperative administration of hMSCs might be more effective to reduce the surgery-induced inflammation as shown in this study.
We used a mouse model in the present study because corneal allotransplantation is the most well-studied in mice and thus the temporal sequence of events from the introduction of the alloantigen to immune rejection is well-established in this model. (Forrester, 2010; Catron, J. Exp. Med., Vol. 203, pgs. 1045-1054 (2006); Kuffova, et al., Transplantation, Vol. 72, pgs. 1292-1298 (2001)). The surgical procedure of transplanting corneas in mouse eyes, however, might have induced more severe tissue damage and surgically-induced inflammation compared to transplantation in humans. Further studies in larger animal models will be beneficial.
The results may explain well the beneficial effects of MSCs observed in various animal models of organ transplantation such as heart, lung, skin, and islets. (Crop, 2009; Casiraghi, et al., J. Immunol., Vol. 181, pgs. 3933-3946 (2008); Jawinen, et al., J. Immunol., Vol. 181, pgs. 4389-4396 (2008); Sbano, et al Arch. Dermatol. Res., Vol. 300, pgs. 115-124 (2008); Ding, et al., Transplantation, Vol. 89, pgs. 270-273 (2010)). In addition, the data may extend upon previous studies that focused mostly on examining immune tolerance as a mechanism for MSCs to improve transplant survival. Early inflammatory responses also may be inviting targets for therapy. The results presented here add another rationale for using MSCs as a primary or secondary therapy to decrease the need for pharmacological immunosuppression in patients with transplants. Moreover, since IV administration of recombinant TSG-6 reproduced many of the beneficial effects of the hMSCs, the results raise the possibility that therapy with the protein may be more practical than therapy with the cells.
In summary, our results suggest that MSCs prolonged the survival of corneal allografts by suppressing the surgery-induced inflammation early after transplantation. The action of MSCs was exerted without significant engraftment of the cells in the cornea and primarily by secreting trophic factors including the anti-inflammatory molecule TSG-6. The observations may account for the favorable effects of MSCs seen previously in models of solid organ and cellular transplantation. Moreover, the data provide a basis for using either MSCs or TSG-6 to improve the survival of transplants of the cornea and possibly other organs.
The disclosures of all patents, publications (including published patent applications), depository accession numbers, and database accession numbers are incorporated herein by reference to the same extent as if each patent, publication, depository accession number, and database accession number were incorporated individually by reference.
It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims.
This Application claims priority based on provisional Application Ser. No. 61/555,717, filed Nov. 4, 2011, the contents of which are incorporated by reference in their entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2012/062972 | 11/1/2012 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 61555717 | Nov 2011 | US |
